772 related articles for article (PubMed ID: 26768436)
1. Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance).
Kottschade L; Novotny P; Lyss A; Mazurczak M; Loprinzi C; Barton D
Support Care Cancer; 2016 Jun; 24(6):2661-7. PubMed ID: 26768436
[TBL] [Abstract][Full Text] [Related]
2. Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance).
Barton DL; Thanarajasingam G; Sloan JA; Diekmann B; Fuloria J; Kottschade LA; Lyss AP; Jaslowski AJ; Mazurczak MA; Blair SC; Terstriep S; Loprinzi CL
Cancer; 2014 Nov; 120(22):3575-83. PubMed ID: 25043153
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan.
Baba Y; Baba H; Yamamoto S; Shimada H; Shibata T; Miyazaki T; Yoshikawa T; Nakajima Y; Tsuji Y; Shimokawa M; Kitagawa Y; Aiba K
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27001532
[TBL] [Abstract][Full Text] [Related]
4. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
[TBL] [Abstract][Full Text] [Related]
5. The incidence of nausea in the absence of vomiting in patients receiving intravenous chemotherapy.
Smit T; Kotze I; du Plessis J
Ann Palliat Med; 2021 Mar; 10(3):2679-2686. PubMed ID: 33549001
[TBL] [Abstract][Full Text] [Related]
6. Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes.
Liau CT; Chu NM; Liu HE; Deuson R; Lien J; Chen JS
Support Care Cancer; 2005 May; 13(5):277-86. PubMed ID: 15770489
[TBL] [Abstract][Full Text] [Related]
7. Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study.
Cruz FM; de Iracema Gomes Cubero D; Taranto P; Lerner T; Lera AT; da Costa Miranda M; da Cunha Vieira M; de Souza Fêde AB; Schindler F; Carrasco MM; de Afonseca SO; Pinczowski H; del Giglio A
Support Care Cancer; 2012 Mar; 20(3):601-6. PubMed ID: 21465325
[TBL] [Abstract][Full Text] [Related]
8. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
10. Clinical Practices and Outcomes on Chemotherapy-Induced Nausea and Vomiting Management in South Korea: Comparison with Asia-Pacific Data of the Pan Australasian Chemotherapy Induced Emesis Burden of Illness Study.
Lee MA; Cho EK; Oh SY; Ahn JB; Lee JY; Thomas B; Jung H; Kim JG
Cancer Res Treat; 2016 Oct; 48(4):1420-1428. PubMed ID: 26875197
[TBL] [Abstract][Full Text] [Related]
11. Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan.
Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
Int J Clin Oncol; 2017 Apr; 22(2):405-412. PubMed ID: 27909835
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.
Rapoport BL; Chasen MR; Gridelli C; Urban L; Modiano MR; Schnadig ID; Poma A; Arora S; Kansra V; Schwartzberg LS; Navari RM
Lancet Oncol; 2015 Sep; 16(9):1079-1089. PubMed ID: 26272769
[TBL] [Abstract][Full Text] [Related]
13. Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).
Rapoport B; Chua D; Poma A; Arora S; Wang Y; Fein LE
Support Care Cancer; 2015 Nov; 23(11):3281-8. PubMed ID: 25940030
[TBL] [Abstract][Full Text] [Related]
14. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study.
Molassiotis A; Aapro M; Dicato M; Gascon P; Novoa SA; Isambert N; Burke TA; Gu A; Roila F
J Pain Symptom Manage; 2014 May; 47(5):839-848.e4. PubMed ID: 24075401
[TBL] [Abstract][Full Text] [Related]
17. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.
Grunberg SM; Deuson RR; Mavros P; Geling O; Hansen M; Cruciani G; Daniele B; De Pouvourville G; Rubenstein EB; Daugaard G
Cancer; 2004 May; 100(10):2261-8. PubMed ID: 15139073
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study.
Naito Y; Kai Y; Ishikawa T; Fujita T; Uehara K; Doihara H; Tokunaga S; Shimokawa M; Ito Y; Saeki T
Breast Cancer; 2020 Jan; 27(1):122-128. PubMed ID: 31407150
[TBL] [Abstract][Full Text] [Related]
19. Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries.
Hsieh RK; Chan A; Kim HK; Yu S; Kim JG; Lee MA; Dalén J; Jung H; Liu YP; Burke TA; Keefe DM
Support Care Cancer; 2015 Jan; 23(1):263-72. PubMed ID: 25120009
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.
Chow R; Tsao M; Chiu L; Popovic M; Milakovic M; Lam H; DeAngelis C
Ann Palliat Med; 2018 Apr; 7(2):221-233. PubMed ID: 29764184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]